Voydeya (Danicopan) for PNH

Overview
Voydeya is approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy to either ravulizumab or eculizumab for the treatment of extravascular hemolysis (destruction of red blood cells outside of blood vessels) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Voydeya is not effective as a standalone treatment and must be used with one of the other two medications. Voydeya is also known by its drug name, danicopan.

Voydeya is a complement factor D inhibitor. It is believed to work by blocking part of the immune system called the complement pathway, which helps reduce red blood cell destruction in people with PNH.

How do I take it?
Prescribing information states that Voydeya is taken by mouth three times a day, with or without food. Treatment typically begins with three doses per day, and the dosing size may be increased based on how well the treatment is working. The drug should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Voydeya include headache.

Rare but serious side effects may include serious and life-threatening infections caused by encapsulated bacteria such as Neisseria meningitidis (which can cause meningitis), Streptococcus pneumoniae (which can cause pneumonia), and Haemophilus influenzae type B (which can cause severe respiratory infections). Other serious risks include elevated liver enzymes (which may indicate liver damage) and hyperlipidemia (high levels of fat in the blood).

For more information about this treatment, visit:
Label: Voydeya — Danicopan Tablet, Film Coated; Voydeya — Danicopan Kit — DailyMed